MX2023013060A - Composiciones y metodos para el tratamiento de tumores neuroendocrinos. - Google Patents
Composiciones y metodos para el tratamiento de tumores neuroendocrinos.Info
- Publication number
- MX2023013060A MX2023013060A MX2023013060A MX2023013060A MX2023013060A MX 2023013060 A MX2023013060 A MX 2023013060A MX 2023013060 A MX2023013060 A MX 2023013060A MX 2023013060 A MX2023013060 A MX 2023013060A MX 2023013060 A MX2023013060 A MX 2023013060A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- neuroendocrine tumors
- treatment
- octreotide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE2130118 | 2021-05-04 | ||
| PCT/SE2022/050404 WO2022235186A1 (en) | 2021-05-04 | 2022-04-26 | Compositions and methods for treating neuroendocrine tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023013060A true MX2023013060A (es) | 2023-11-15 |
Family
ID=83932120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013060A MX2023013060A (es) | 2021-05-04 | 2022-04-26 | Composiciones y metodos para el tratamiento de tumores neuroendocrinos. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250281569A1 (https=) |
| EP (1) | EP4333874A4 (https=) |
| JP (1) | JP2024517204A (https=) |
| KR (1) | KR20240004706A (https=) |
| CN (1) | CN117241822A (https=) |
| AU (1) | AU2022271139A1 (https=) |
| CA (1) | CA3217408A1 (https=) |
| IL (1) | IL308133A (https=) |
| MX (1) | MX2023013060A (https=) |
| WO (1) | WO2022235186A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4731247A1 (en) * | 2023-06-20 | 2026-04-29 | Camurus AB | Compositions and methods for treating acromegaly |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103702662B (zh) * | 2011-05-25 | 2018-07-20 | 卡穆鲁斯公司 | 控制释放肽制剂 |
| GB201402423D0 (en) * | 2014-02-12 | 2014-03-26 | New Injection Systems Ltd | Auto-injector assembly |
| MX383392B (es) * | 2016-09-27 | 2025-03-13 | Camurus Ab | Mezclas y formulaciones que comprenden una sal de alquil amonio de ácido etilendiaminotetraacético (edta). |
| WO2020240018A1 (en) * | 2019-05-29 | 2020-12-03 | Camurus Ab | Administration device & regime |
-
2022
- 2022-04-26 IL IL308133A patent/IL308133A/en unknown
- 2022-04-26 JP JP2023567060A patent/JP2024517204A/ja active Pending
- 2022-04-26 CA CA3217408A patent/CA3217408A1/en active Pending
- 2022-04-26 AU AU2022271139A patent/AU2022271139A1/en active Pending
- 2022-04-26 US US18/558,623 patent/US20250281569A1/en active Pending
- 2022-04-26 WO PCT/SE2022/050404 patent/WO2022235186A1/en not_active Ceased
- 2022-04-26 KR KR1020237041028A patent/KR20240004706A/ko active Pending
- 2022-04-26 CN CN202280032371.0A patent/CN117241822A/zh active Pending
- 2022-04-26 EP EP22799203.9A patent/EP4333874A4/en active Pending
- 2022-04-26 MX MX2023013060A patent/MX2023013060A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4333874A1 (en) | 2024-03-13 |
| AU2022271139A1 (en) | 2023-10-12 |
| WO2022235186A1 (en) | 2022-11-10 |
| CN117241822A (zh) | 2023-12-15 |
| US20250281569A1 (en) | 2025-09-11 |
| IL308133A (en) | 2023-12-01 |
| KR20240004706A (ko) | 2024-01-11 |
| JP2024517204A (ja) | 2024-04-19 |
| CA3217408A1 (en) | 2022-11-10 |
| EP4333874A4 (en) | 2025-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021003222A1 (es) | (divisional de solicitud 400-2021) métodos para reducir la necesidad de revascularización arterial periférica en un sujeto tratado con estatinas. | |
| CL2021001810A1 (es) | Combinación de dextrometorfano y bupropión para el tratamiento de depresión | |
| MX2022011748A (es) | Composiciones orales de inhibidor de ruta de mk2 para el tratamiento de condiciones inmunitarias. | |
| AR044007A1 (es) | Metodos para el tratamiento de la enfermedad de parkinson | |
| CL2022000458A1 (es) | Ciertos compuestos de pladienolida y métodos de uso. (divisional de solicitud 202002604) | |
| AR049985A1 (es) | Tratamiento de combinacion para enfermedades malignas no hematologicas | |
| AR046163A1 (es) | Combinaciones de farmacos para el tratamiento de neoplasmas | |
| NI201100147A (es) | Métodos para tratar infartos agudos de miocardio y trastornos relacionados. | |
| RU2014102940A (ru) | Композиция противораковой вакцины, содержащая пептид wt1, для трансдермального введения | |
| MX2015017307A (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington. | |
| EA202191079A1 (ru) | Способы лечения синдрома ретта с применением фенфлурамина | |
| AR120399A1 (es) | Un método de tratamiento de un cáncer positivo para dll3 | |
| UY39510A (es) | Compuestos macrocíclicos y métodos para usarlos | |
| CL2021000882A1 (es) | Formulaciones y métodos para tratar las nauseas y vómitos inducidos por la quimioterapia. | |
| PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
| AR110800A1 (es) | MÉTODOS PARA AUMENTAR EN PLASMA SANGUÍNEO LA 2-DESOXIURIDINA (dUrd) Y LA INHIBICIÓN DE LA TIMIDILATO SINTASA | |
| MX2023013060A (es) | Composiciones y metodos para el tratamiento de tumores neuroendocrinos. | |
| CO2022008690A2 (es) | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso | |
| AR084216A1 (es) | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit | |
| UY39516A (es) | Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión | |
| CL2021000627A1 (es) | Composiciones farmacéuticas adecuadas para liberación articular y su uso en el tratamiento del dolor articular | |
| CL2021001397A1 (es) | Vibegrón para el tratamiento de los síntomas de la vejiga hiperactiva | |
| CO2026000331A2 (es) | Inhibidores de tyk2 y composiciones y métodos de estos | |
| CO2023004447A2 (es) | Composiciones y métodos para el tratamiento de distrofias musculares | |
| BR112023015440A2 (pt) | Métodos de tratamento de câncer usando uma combinação de regimes de dosagem com serd |